This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Coalition Of U.S. Women's Health And HIV Advocates Call For Accelerated US Government Plan For Demonstrating Feasibility Of PrEP For Women

VOICE Results Underscore Need for Clear, US-Based PrEP Implementation Agenda

ATLANTA, March 4, 2013 /PRNewswire-USNewswire/ -- The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women's health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection.

The Working Group called for a US federal coordinating group to be convened with the goal of ensuring that plans and funds are in place for demonstration projects that will answer key questions about the use of daily tenofovir/emtricitibine (TDF/FTC, brand name Truvada) as pre-exposure prophylaxis (PrEP) among women in the United States, as well as plans for educational campaigns for women, their partners and health care providers as PrEP is rolled out.

"Many women in the US are at high risk for HIV. In some communities African American women are at as much risk of HIV as in many African communities and they need new HIV prevention options that they can control and use to protect themselves. PrEP can be that option for some women. The scientific evidence is clear, and last year's FDA approval of Truvada as PrEP for all men and women at risk of HIV paved the way for the next steps," said Dazon Dixon Diallo, MPH, Executive Director of SisterLove and convener of the Working Group.

"While the clinical science is clear, the social and behavioral implications are less so, and we now need to develop and fund demonstration projects that will help answer a range of questions about real-world use of PrEP by American women and move toward an integrated plan for PrEP rollout in our communities that includes support for healthcare providers, social workers and others who will help women use PrEP effectively," Diallo added.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,391.42 -25.43 -0.15%
S&P 500 2,017.96 -3.29 -0.16%
NASDAQ 4,684.4380 +1.0310 0.02%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs